Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Robinson Pharma, Inc.Robinson Pharma, Inc. Receives "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026Robinson Pharma, Inc. (RPI), a premier full-service contract manufacturer of dietary supplements and nutraceuticals, is proud to announce that it has been honored by Bausch + Lomb with the "Above and Beyond" Supplier Award for the month of...
- COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERINGCOSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to announce, further to the press release dated September 10, 2026, the closing of the second tranche of a non-brokered private placement of the 15% unsecured convertible debentures (the “Offering”).
- Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for HLHS
- AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class ActionInvestors who lost money in AARD after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
- Skyhawk Therapeutics gibt die endgültigen Ergebnisse nach 15 Monaten aus der klinischen Phase-1/2-Studie mit SKY-0515 bei Patienten mit Huntington-Krankheit bekanntDer Datensatz über einen Zeitraum von fünfzehn Monaten stellt die abschließende Auswertung der Phase-1/2-Studie dar. Zum primären Messzeitpunkt im 15. Monat wiesen die mit SKY-0515 behandelten Patienten im Vergleich zur überlappungsgewichteten externen Kontrollgruppe für den natürlichen...
- Braveheart Bio to Participate in Stifel Cardiometabolic ForumBraveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Stifel Virtual Cardiometabolic Forum, being held September 30. Management will participate in a fireside chat on Wednesday, September 30, 2026, at 12:30 p.m. EDT.
- AbCelleraAbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026VANCOUVER, British Columbia, September 16, 2026--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
- Kaplan Fox & Kilsheimer LLPKaplan Fox Alerts Capricor Therapeutics, Inc. (CAPR) Investors Seeking Recovery to a Securities Class Action Deadline on September 28, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us. You may...
- Myosin Therapeutics Inc.Myosin Therapeutics Selected for 2026-2027 NCI Investor Initiatives ShowcaseMyosin Therapeutics, Inc., a clinical-stage biotechnology company developing a new class of therapies targeting cancer cell mechanics, today announced its selection as a 2026–2027 National Cancer Institute (NCI) Investor Initiatives Showcase...
- Alberta Cancer FoundationJack Ady Cancer Centre launches Alberta's first researcher-led cancer clinical trial outside major urban centresDonor-supported study will evaluate whether prostate cancer radiation treatments can be safely reduced from five sessions to two
- Suvoda earns two PM360 Innovation Awards for Sofia AI assistant and Suvoda AppSuvoda wins two PM360 Innovation Awards for Sofia AI assistant for clinical trials, and the Suvoda App, easing burdens for sites, sponsors, and patients.
- Avacta Group PLC LONDON andAvacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 TrialAvacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces today that it has achieved clinical proof of mechanism for AVA6103, its next-generation controlled-release pre|CISION® peptide-drug conjugate (PDC) platform in the ongoing phase 1 FOCUS-01 trial.